optic: a dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid l...
Published 4 years ago • 59 plays • Length 6:16Download video MP4
Download video MP3
Similar videos
-
7:02
interim analysis from the optic trial, a dose-ranging study of ponatinib for cp-cml
-
2:59
optic 3-year update: dose-optimization of 3 starting doses of ponatinib in cp-cml
-
1:38
an update on the optic study: adjusting the dose of ponatinib for cp-cml
-
1:37
optic: ponatinib in chronic-phase cml
-
3:31
ash 2021: new optic trial analysis shows ponatinib is effective in chronic myeloid leukemia patients
-
4:44
ponatinib in chronic-phase cml patients with prior second generation tki exposure
-
6:39
fda approves new dosing for ponatinib to treat chronic myeloid leukemia
-
1:43
dosing strategy of ponatinib in cp-cml: insights from the optic trial
-
4:19
optic: ponatinib in resistant chronic-phase cml
-
7:47
is ponatinib safe for treating cml?
-
1:40
using ponatinib to treat highly resistant chronic myeloid leukemia, results from a phase i trial
-
1:35
safety of ponatinib in chronic-phase chronic myeloid leukemia (cml) patients
-
5:10
jorge e cortes asco20: interim analysis of the phase ii optic trial of ponatinib in cp-cml
-
8:00
dr. cortes discusses approval of ponatinib for adults with chronic-phase cml
-
1:35
optic post hoc analyses: optic and pace comparison & impact of mutations on ponatinib starting dose
-
3:20
case 1: ponatinib in chronic-phase cml
-
2:20
dose modification of ponatinib in cp-cml: data from the pace and optic trials
-
5:03
role of ponatinib in treatment of r/r cml
-
2:50
epic:phase 3 trial of ponatinib compared with imatinib in newly diagnosed chronic myeloid leukemia